Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
i-Lumen Scientific
AddedFeb 15, 2024
UpdatedJun 18, 2026
i-Lumen Scientific

i-Lumen Scientific

Series B

i-Lumen Scientific: Innovating noninvasive therapies for dry age-related macular degeneration.

HQ
Bloomington, MN, US
Founded
2015
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to revolutionize ophthalmic care, i-Lumen Scientific focuses on developing noninvasive therapies for dry age-related macular degeneration (dAMD). The company aims to address the significant unmet needs in ophthalmology by improving eyesight in patients affected by this condition. Their flagship product, the i-LUMEN™ system, is a software-based medical device designed to deliver innovative, non-invasive treatment, potentially transforming the standard of care for dAMD patients.nni-Lumen Scientific has garnered attention from notable figures in the biotech and ophthalmology sectors, securing investments from key industry players.

The company's pioneering approach has led to significant advancements in noninvasive retinal therapy, positioning it as a leader in the field. With its groundbreaking technology, i-Lumen Scientific is making a substantial impact on the lives of individuals suffering from dAMD, offering hope and improved vision through cutting-edge solutions.

i-Lumen Scientific - Quick Facts

When was i-Lumen Scientific founded?

i-Lumen Scientific was founded in 2015.

Where is i-Lumen Scientific's headquarters located?

i-Lumen Scientific's headquarters is located in Bloomington, MN, US.

When was i-Lumen Scientific's last funding round?

i-Lumen Scientific's most recent funding round was for $18M (USD) in April 2022.

How much has i-Lumen Scientific raised to-date?

As of Apr 26, 2022, i-Lumen Scientific has raised a total of $18.8M (USD).

How many employees does i-Lumen Scientific have?

i-Lumen Scientific has 5 employees as of Feb 5, 2024.

i-Lumen Scientific - Classification

Industry
  • Hardware
Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Medical Devices
  • Therapeutics
Tags
  • Biotech
  • Healthcare
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies
Show 7 more industry codes
NAICS
  • 330000Manufacturing
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified